S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

Akebia Therapeutics News Headlines (NASDAQ:AKBA)

$6.28
-0.13 (-2.03 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$6.07
Now: $6.28
$6.55
50-Day Range
$3.16
MA: $4.45
$6.42
52-Week Range
$2.99
Now: $6.28
$10.45
Volume1.23 million shs
Average Volume1.13 million shs
Market Capitalization$746.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Headlines

Akebia Therapeutics (NASDAQ AKBA) News Headlines

Source:
DateHeadline
Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc (AKBA) ?Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc (AKBA) ?
finance.yahoo.com - December 11 at 5:23 PM
$95.40 Million in Sales Expected for Akebia Therapeutics Inc (NASDAQ:AKBA) This Quarter$95.40 Million in Sales Expected for Akebia Therapeutics Inc (NASDAQ:AKBA) This Quarter
www.americanbankingnews.com - December 8 at 4:20 AM
-$0.43 EPS Expected for Akebia Therapeutics Inc (NASDAQ:AKBA) This Quarter-$0.43 EPS Expected for Akebia Therapeutics Inc (NASDAQ:AKBA) This Quarter
www.americanbankingnews.com - December 6 at 3:44 AM
Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) StockOptions Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock
finance.yahoo.com - December 2 at 12:44 PM
Contrasting Akebia Therapeutics (NASDAQ:AKBA) & Bicycle Therapeutics (NASDAQ:BCYC)Contrasting Akebia Therapeutics (NASDAQ:AKBA) & Bicycle Therapeutics (NASDAQ:BCYC)
www.americanbankingnews.com - December 2 at 11:01 AM
Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five YearsIntroducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years
finance.yahoo.com - December 2 at 7:43 AM
Akebia Therapeutics Inc (NASDAQ:AKBA) Given Consensus Recommendation of "Hold" by AnalystsAkebia Therapeutics Inc (NASDAQ:AKBA) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 2 at 7:19 AM
Large Option Trader Betting On Biotech Stock Akebia Following Insider BuysLarge Option Trader Betting On Biotech Stock Akebia Following Insider Buys
finance.yahoo.com - November 26 at 3:31 PM
AKBA Akebia Therapeutics, Inc. Common StockAKBA Akebia Therapeutics, Inc. Common Stock
www.nasdaq.com - November 23 at 9:46 AM
Why Akebia Therapeutics Stock Is Jumping TodayWhy Akebia Therapeutics Stock Is Jumping Today
www.fool.com - November 22 at 5:27 PM
Akebia Therapeutics: Vadadustat Approval Seems Make Or BreakAkebia Therapeutics: Vadadustat Approval Seems Make Or Break
seekingalpha.com - November 22 at 5:27 PM
Akebia Therapeutics Inc (NASDAQ:AKBA) SVP Buys $96,660.00 in StockAkebia Therapeutics Inc (NASDAQ:AKBA) SVP Buys $96,660.00 in Stock
www.americanbankingnews.com - November 22 at 8:55 AM
Insider Buying: Akebia Therapeutics Inc (NASDAQ:AKBA) Director Acquires 5,800 Shares of StockInsider Buying: Akebia Therapeutics Inc (NASDAQ:AKBA) Director Acquires 5,800 Shares of Stock
www.americanbankingnews.com - November 22 at 8:55 AM
John P. Butler Purchases 50,000 Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) StockJohn P. Butler Purchases 50,000 Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) Stock
www.americanbankingnews.com - November 21 at 9:52 AM
Akebia Therapeutics: No Change To The Thesis, And The Lower Entry Point Improves The BetAkebia Therapeutics: No Change To The Thesis, And The Lower Entry Point Improves The Bet
seekingalpha.com - November 19 at 11:16 PM
Akebia Therapeutics (AKBA) "Buy" Rating Reiterated at MizuhoAkebia Therapeutics' (AKBA) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - November 19 at 3:02 PM
HC Wainwright Trims Akebia Therapeutics (NASDAQ:AKBA) Target Price to $16.00HC Wainwright Trims Akebia Therapeutics (NASDAQ:AKBA) Target Price to $16.00
www.americanbankingnews.com - November 19 at 10:43 AM
Edited Transcript of AKBA earnings conference call or presentation 12-Nov-19 2:00pm GMTEdited Transcript of AKBA earnings conference call or presentation 12-Nov-19 2:00pm GMT
finance.yahoo.com - November 18 at 7:24 PM
Akebia Therapeutics Inc (AKBA) Q3 2019 Earnings Call TranscriptAkebia Therapeutics Inc (AKBA) Q3 2019 Earnings Call Transcript
www.nasdaq.com - November 14 at 12:34 AM
$100 Million Loan Overshadows Akebia Therapeutics Q3 Earnings Miss$100 Million Loan Overshadows Akebia Therapeutics' Q3 Earnings Miss
www.fool.com - November 12 at 5:50 PM
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial ResultsAkebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 12 at 12:49 PM
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue EstimatesAkebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 12 at 12:49 PM
Akebia Announces Positive 52-week Efficacy and...Akebia Announces Positive 52-week Efficacy and...
www.benzinga.com - November 9 at 2:25 PM
Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney DiseaseAkebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease
finance.yahoo.com - November 9 at 2:25 PM
Can Akebia Therapeutics (NASDAQ:AKBA) Afford To Invest In Growth?Can Akebia Therapeutics (NASDAQ:AKBA) Afford To Invest In Growth?
finance.yahoo.com - November 1 at 12:16 PM
Akebia Therapeutics Inc (AKBA) Is Burning These Hedge FundsAkebia Therapeutics Inc (AKBA) Is Burning These Hedge Funds
finance.yahoo.com - October 30 at 12:56 PM
Akebia Therapeutics to Report Third Quarter 2019 Financial Results and Discuss Recent Business HighlightsAkebia Therapeutics to Report Third Quarter 2019 Financial Results and Discuss Recent Business Highlights
finance.yahoo.com - October 28 at 12:45 PM
Akebia TherapeuticsAkebia Therapeutics
www.fool.com - October 24 at 11:23 PM
Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual MeetingAkebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting
finance.yahoo.com - October 24 at 8:22 AM
Akebia sues feds over dropped Auryxia coverageAkebia sues feds over dropped Auryxia coverage
seekingalpha.com - October 15 at 7:28 PM
Should You Worry About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Pay Cheque?Should You Worry About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Pay Cheque?
finance.yahoo.com - October 2 at 3:38 PM
Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare ConferenceAkebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
finance.yahoo.com - September 24 at 11:41 AM
Akebia completes enrollment in late-stage vadadustat programAkebia completes enrollment in late-stage vadadustat program
seekingalpha.com - September 3 at 7:23 PM
How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility?How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility?
finance.yahoo.com - September 2 at 6:21 PM
Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMTEdited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT
finance.yahoo.com - August 11 at 9:25 AM
Akebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call TranscriptAkebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 10 at 11:14 AM
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business HighlightsAkebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights
finance.yahoo.com - August 8 at 9:18 AM
Akebia settles Auryxia patent dispute with Par PharmaAkebia settles Auryxia patent dispute with Par Pharma
seekingalpha.com - August 5 at 8:13 PM
Akebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par PharmaceuticalAkebia Therapeutics® Announces Settlement of Auryxia® Patent Litigation with Par Pharmaceutical
finance.yahoo.com - August 5 at 9:34 AM
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - August 3 at 1:50 AM
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Weeks ReleaseAkebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
www.nasdaq.com - August 1 at 11:38 PM
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseAkebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
finance.yahoo.com - August 1 at 11:38 PM
What Type Of Shareholder Owns Akebia Therapeutics, Inc.'s (NASDAQ:AKBA)?What Type Of Shareholder Owns Akebia Therapeutics, Inc.'s (NASDAQ:AKBA)?
finance.yahoo.com - July 27 at 12:43 AM
Akebia Therapeutics to Report Second Quarter 2019 Financial ResultsAkebia Therapeutics to Report Second Quarter 2019 Financial Results
finance.yahoo.com - July 26 at 1:05 AM
Akebia Therapeutics: Still A Strong Buy After The 50% DeclineAkebia Therapeutics: Still A Strong Buy After The 50% Decline
seekingalpha.com - July 16 at 9:10 AM
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care PartnersAkebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners
finance.yahoo.com - July 11 at 8:46 AM
Akebia up 2% premarket on successful Riona study in JapanAkebia up 2% premarket on successful Riona study in Japan
seekingalpha.com - July 10 at 8:57 AM
Why Akebia Therapeutics Is A Worthwhile Contrarian BetWhy Akebia Therapeutics Is A Worthwhile Contrarian Bet
seekingalpha.com - July 10 at 8:57 AM
Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in JapanAkebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
finance.yahoo.com - July 10 at 8:57 AM
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
finance.yahoo.com - June 20 at 7:08 PM
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel